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Executive Summary 
 
 
The Task Force to Study Cervical Cancer Prevention, Detection and Education (“Task 
Force”) was established in the First Regular Session of the 122nd Legislature by Resolves 2005, 
Chapter 121. The Task Force is authorized to meet over a two-year period to examine the 
prevalence and incidence of cervical cancer in Maine, to review preventive strategies and new 
technologies, to assess existing laws, programs and services, and, ultimately, to develop a 
statewide cervical cancer prevention plan and strategies for plan implementation and 
coordination.  As created, the 16-member Task Force includes one member of the Senate, two 
members of the House of Representatives, eight members representing different medical 
organizations, associations and specialties, one member representing the health insurance 
industry, one member representing communications consultants, one member representing 
cervical cancer survivors and two representatives of the Maine Department of Health and Human 
Services.  
 
The Task Force was convened on November 16, 2005 and held a second meeting on 
December 20, 2005.  Task Force members received program information and data regarding 
screening and treatment services within the state including the Maine Cancer Registry, the 
Maine Breast and Cervical Health program and MaineCare coverage of cervical cancer services.  
The Task Force also received information regarding clinical and technology issues relating to 
cervical cancer screening.  
 
In accordance with the authorizing legislation, the Task Force will not meet from 
December 21, 2005 to April 25, 2006.  To complete its work, the Task Force anticipates holding 
2 meetings between April 26, 2005 and June 30, 2006 (the end of the state fiscal year 2005-
2006) and 4 meetings between July 1, 2006 and November 1, 2006.  The Task Force will utilize 
its future meetings to: 
 
• Further examine key clinical and technological issues related to cervical cancer 
prevention and detection;   
 
• Identify and address gaps in cervical cancer prevention, detection and education; and 
 
• Develop a statewide cervical cancer prevention plan and strategies for plan 
implementation and coordination.   
 
The Task Force will then submit its findings, recommendations and any proposed 
legislation in its final report, due November 1, 2006, to the joint standing committee of the 
legislature having jurisdiction over health and human services matters.  
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I. Introduction 
 
The Task Force to Study Cervical Cancer Prevention, Detection and Education (“Task 
Force”) was established in the First Regular Session of the 122nd Legislature by Resolves 2005, 
Chapter 121.   A copy of the law is attached in Appendix A.  As created, the 16-member Task 
Force includes one member of the Senate, two members of the House of Representatives, eight 
members representing different medical organizations, associations and specialties, one member 
representing the health insurance industry, one member representing communications 
consultants, one member representing cervical cancer survivors and two representatives of the 
Maine Department of Health and Human Services. The Task Force membership roster is listed in 
Appendix B.  
 
The Task Force was established to examine the prevalence and incidence of cervical 
cancer in Maine, to review preventive strategies and new technologies, to assess existing laws, 
programs and services, and, ultimately, to develop a statewide cervical cancer prevention plan 
and strategies for plan implementation and coordination.  Specifically, the Task Force was 
charged with the following six duties: 
 
1. Review statistical and qualitative data on the prevalence and incidence of cervical cancer 
in Maine; 
 
2. Review preventive strategies and new technologies, including newly introduced vaccines 
and their effectiveness in preventing and controlling the risk of cervical cancer, as well as 
their relative costs; 
 
3. Identify and examine the strengths and limitations of existing laws, regulations, programs 
and services regarding coverage and awareness of cervical cancer; 
 
4. Consider reports and testimony from individuals, local health departments, community-
based organizations, voluntary health organizations and other public and private 
organizations statewide to learn more about their contributions to cervical cancer 
diagnosis, prevention and treatment and their ideas for improving prevention, diagnosis 
and treatment in Maine; 
 
5. Develop, in consultation with the Department of Health and Human Services, a statewide 
comprehensive cervical cancer prevention plan and strategies for plan implementation 
and for promoting the plan and awareness of the causes, risk factors, prevention, early 
detection and treatment of cervical cancer to the general public, state and local elected 
officials and various public and private organizations, associations, businesses, industries 
and agencies; and 
 
6. Recommend strategies for coordination and communication among state and local 
agencies and organizations regarding their involvement in achieving the aims of the 
cervical cancer prevention plan. 
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Resolves 2005, chapter 121 requires the Task Force to submit two reports: 
 
1. An initial report to the Joint Standing Committee on Health and Human Services and 
to the Governor in December 2005;1 and 
 
2. A final report to the Joint Standing Committee on Health and Human Services by 
November 1, 2006.  
 
The resolve authorizes the joint standing committee of the Legislature having jurisdiction over 
health and human services matters in the First Regular Session of the 123rd Legislature to report 
out legislation on cervical cancer prevention, detection and education.  
 
 
II. Task Force Progress and Meetings  
 
 Appointments to the Task Force were completed on October 19, 2005, and the Task 
Force convened for its first meeting on November 16, 2005. The Task Force held a second 
meeting on December 20, 2005.   
 
 A. First Meeting of the Task Force 
 
The first meeting focused on laying the foundation for the work of the Task Force. The 
meeting included three main components: 
 
1. A review of the authorizing legislation and Task Force goals, 
2. An overview of cervical cancer initiatives within the Maine Department of Health 
and Human Services, and 
3. An opportunity to discuss and identify priorities for the Task Force within the context 
of its required duties. 
 
1. Authorizing Legislation and Task Force Goals 
 
Task Force members reviewed the authorizing legislation, Resolves 2005, chapter 121, 
with particular focus on the duties and reporting requirements described in the Introduction 
above (see also Appendix A).  Members discussed the motivation and underlying goals for the 
Task Force and identified the following justifications for undertaking this work: 
 
• While Maine is doing relatively well in the areas of cervical cancer prevention, 
detection and education, there is an opportunity for the State to further reduce the 
rate of cervical cancer given the current technology and to move toward complete 
eradication of cervical cancer with the development and introduction of new 
technology, and  
                                                 
1 The deadline for the initial report in Resolves 2005, chapter 121, was December 7, 2005. The Task Force 
requested an extension of the reporting deadline from the Legislative Council to December 23, 2005; that extension 
was approved by the Council on November 28, 2005. 
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• There are gaps in the current system of cervical cancer prevention, detection and 
education in the State that need to be addressed. 
 
2. Cervical Cancer Initiatives within DHHS  
 
The Task Force invited representatives of the Maine Department of Health and Human 
Services to present information on the Maine Cancer Registry and the Maine Breast and Cervical 
Health Program. 
 
a. Maine Cancer Registry 
 
The Maine Cancer Registry (MCR) is a statewide population-based cancer surveillance 
system established by the Legislature in 1983 (22 MRSA, Chapter 255).   MCR collects patient 
demographic, diagnosis and initial treatment information on all cancer cases diagnosed in Maine, 
except for basal cell and squamous cell carcinoma of the skin.  Information is collected from 
hospitals, health care facilities, physicians and other health care providers who diagnose or treat 
cancer patients. The law requires these individuals and facilities to report new cases to the MCR 
within 6 months of seeing the patient.  MCR is partially funded by the National Program of 
Cancer Registries, a program of the U.S. Department of Health and Human Services, Centers for 
Disease Control and Prevention (CDC). 
 
MCR issues a “Cancer Incidence and Mortality Report” which includes statistical 
comparisons between cancer incidence and mortality rates in Maine and the nation for various 
cancer types, including cervical cancer.  This information is used to monitor and evaluate cancer 
incidence trends in Maine, to identify areas in need of public health interventions and to improve 
cancer prevention, treatment and control. The latest data from the MCR shows that the rates of 
cervical cancer incidence and mortality in Maine are similar to the rest of the nation: 2  
 
Table 1 
Cervical Cancer Age-Adjusted Incidence and Mortality Rates 
 
Incidence Rate  
per 100,000 
Mortality Rate 
per 100,000 
 
 
Year Maine National Maine National 
2000 6.5 7.3 1.8 2.5 
2001  9.2 7.3 1.6 2.4 
2002 7.1 6.8 2.2 2.3 
 
b. Maine Breast and Cervical Health Program 
 
                                                 
2 The differences in rates of cervical cancer incidence and mortality in Maine compared with the nation are not 
statistically significant. The National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) 
collects cancer information from 13 population based registries representing approximately 14% of the U.S. 
Population. Because the population in Maine is 98% white, the Maine Cancer Registry uses the SEER White data as 
a national comparison. 
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In 1990, Congress enacted the Breast and Cervical Cancer Mortality Prevention Act 
which established the National Breast and Cervical Cancer Early Detection Program 
(NBCCEDP), the first and only national cancer screening program.  This program, which is 
administered by CDC, provides free breast and cervical cancer screening and related diagnostic 
services for low income and uninsured women.  The federal law does not authorize the CDC to 
pay for treatment services for those women diagnosed with breast or cervical cancer.  
 
Maine is one of over 60 states and tribal organizations that has received funding from the 
CDC to implement a comprehensive breast and cervical cancer program.  Established in 1994, 
the Maine Breast and Cervical Health Program (MBCHP) is administered through the Maine 
Department of Health and Human Services in collaboration with Medical Care Development, 
Inc.  Key features of the program are as follows: 
 
• Funding. Currently, Maine receives $1.8 million annually from the CDC for this 
program. These federal funds are supplemented with approximately $381,000 in 
state General Fund dollars. 
 
• Eligibility. To be eligible for MBCHP, a woman must: be age 40 years and older; 
have income at or below 250% of the federal poverty level; be uninsured or 
underinsured; and be a resident of Maine or New Hampshire.3 
 
• Enrollment. Since its inception, MBCHP has enrolled over 15,000 women and 
provided 23,349 Pap tests and diagnosed 57 cases of cervical cancer. As of 
December 7, 2005, there were 5,321 women currently enrolled in MBCHP. Of 
these women, 33% were 40-49 years of age, 64% were 50-59 years and 3% were 
65 years or older. The MBCHP enrollment rate by county ranged from a low of 
6.8% of eligible women enrolled in Cumberland County to a high of 38.5% of 
eligible women enrolled in Washington County.4   
 
• Covered clinical services. For enrollees, the MBCHP provides an annual exam, 
including a clinical breast exam, pelvic exam, Pap test and HPV testing. Cancer 
treatment is not covered by MBCHP but, in most cases, is covered by MaineCare 
(Medicaid) pursuant to the federal Breast and Cervical Treatment Act of 2000.  
 
• Service delivery system and outreach. MBCHP funds nearly 300 sites to provide 
clinical and educational services. These include: primary care provider sites 
which provide clinical exams and pap tests; other health care professionals who 
provide diagnostic services on referral; laboratory facilities that provide cytology 
and pathology services; and community partnerships that provide public 
education and other support services.  In 2005, the MBCHP distributed 70,000 
program brochures and 1,900 posters to 441 sites across the state.  
 
                                                 
3 The CDC gives the option of eligibility starting at age 18; due to the limited funding for MBCHP and the 
availability of family planning services for younger women, Maine decided to begin eligibility at age 40.  
4 Source: Maine Department of Health and Human Services, Maine Breast and Cervical Health Program.  
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3. Task Force Priorities 
 
Throughout its first meeting, the Task Force relied on the expertise of its members to 
identify priorities to guide the group in the remainder of its work to address cervical cancer 
prevention, detection and education.  At the meeting, members specifically identified the 
following priorities:  
 
• Examine key clinical and technological issues related to cervical cancer 
prevention and detection, as follows: 
 
o Review national clinical guidelines for cervical cancer screening, 
o Evaluate existing Pap test technologies: thin prep and traditional pap, 
o Examine HPV testing issues, and 
o Track the development of new HPV vaccines; and 
 
• Identify and address gaps in cervical cancer prevention, detection and education, 
as follows: 
 
o Develop strategies to address unmet needs of two distinct populations: (1) 
women who are not getting screened, and (2) women who are screened but for 
whom screening fails, 
o Explore opportunities to address the needs of women under 40 years, who are 
presently ineligible for MBCHP, and 
o Assess existing public education and outreach strategies and develop new 
strategies to improve access to screening and treatment services, including 
outreach to immigrant and minority populations. 
 
B. Second Meeting of the Task Force 
 
The second meeting of the Task Force, on December 20, 2005, focused on clinical issues 
relating to cervical cancer screening and gathering additional information on screening and 
treatment services within the state, including MaineCare coverage of cervical cancer services.   
 
1. Cervical Cancer Screening  
 
a. Screening Guidelines 
 
Task Force members reviewed and discussed the current cervical cancer screening 
guidelines provided by three groups: (1) the American Cancer Society (ACS), (2) the U.S. 
Preventive Services Task Force5 (USPSTF), and (3) the American College of Obstetricians and 
                                                 
5 The USPSTF, sponsored by the U.S. DHHS Agency for Healthcare Research and Quality (AHRQ), is an 
independent panel of experts in primary care and prevention that reviews the scientific evidence of effectiveness 
and develops recommendations for clinical preventive services.   
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Gynecologists (ACOG).  As shown in Table 2, the recommended starting point for screening is 
similar across the three groups, but the recommendations for how often to screen for cervical 
cancer and when to stop screening differ across the groups.  Task force members noted that these 
differences in the recommendations were not surprising given that each group had its own 
process and methodology for developing its guidelines.  
 
Table 2 
Cervical Cancer Screening Guidelines6 
 
 
 
 
Recommendation 
 
American Cancer 
Society  
(Nov. 2002) 
U.S. Preventive 
Services Task 
Force  
(Jan. 2003) 
American College 
of Obstetricians 
and Gynecologists 
(Aug. 2003) 
When to Start Screening Approximately 3 
years after onset of 
vaginal intercourse, 
but no later than age 
21 
Within 3 years of 
onset of sexual 
activity or age 21, 
whichever comes 
first 
Approximately 3 
years after onset of 
sexual intercourse, 
but no later than age 
21 
Screening Interval    
 If conventional Pap smear test a) Annually  
b) Every 2-3 years 
for women ≥30 yrs 
with 3 negative 
cytology tests 
At least every 3 
years 
a) Annually 
b) Every 2-3 years 
for women ≥30 yrs 
with 3 negative 
cytology tests 
  
If liquid-based cytology test  
 
a) Every 2 years  
b) Every 2-3 years 
for women ≥30 yrs 
with 3 negative 
cytology tests  
 
Insufficient 
evidence 
 
a) Annually 
b) Every 2-3 years 
for women ≥30 yrs 
with 3 negative 
cytology tests 
 
If HPV testing used 
 
Every 3 years if 
HPV negative, 
cytology negative 
 
Insufficient 
evidence 
 
Every 3 years if 
HPV negative, 
cytology negative 
When to Stop Screening Women ≥ 70 yrs 
with ≥ 3 recent, 
consecutive 
negative tests and 
no abnormal tests in 
prior 10 years 
Women > 65 yrs 
with negative tests, 
who are not 
otherwise at high 
risk for cervical 
cancer 
Inconclusive 
evidence to 
establish upper age 
limit 
  
 b. Understanding Cervical Cancer Screening Failure 
 
 The Task Force reviewed information regarding the factors that contribute to the failure 
of cervical cancer screening to prevent the development of cervical cancer.  Given the existing 
screening technology, it is estimated that 95% of cervical cancer could be prevented under 
                                                 
6 U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 
http://www.cdc.gov/std/HPV/ScreeningTables.pdf 
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perfect conditions.7  In reality, 30% of cervical cancer cases are not prevented as a result of 
imperfections, or failures, in the screening system.  Screening failures can be divided into two 
major types:  
 
1. Insufficient screening. Approximately 65-70% of screening failures are the result of 
women not being screened, including women who are never screened and women who 
are not meeting the recommended guidelines for onset and frequency of screening; and  
 
2. False negative screening. Approximately 30-35% of screening failures are the result of 
“false negative” screening, in which a woman is screened but still develops cervical 
cancer.  
 
c. Cervical Cancer Screening Technology – Conventional Pap Smear and Thin Prep  
  
 To understand the state of current cervical cancer screening technology, the Task Force 
reviewed the differences between the conventional Pap smear and the newer ThinPrep Pap test. 
A number of advantages of the ThinPrep technology were identified, including: 
 
? More effective than conventional Pap smear in detecting low-grade and high-grade 
lesions (specifically squamous intraepithelial lesions, or SILs); 
? Provides higher quality sample than conventional Pap smear (ease of sample collection is 
a contributing factor); and  
? The sample is good for 30 days and can be used for follow-up testing for Human 
Papillomavirus (HPV) without requiring the patient to return for another test. 
 
Despite the advantages of the ThinPrep Pap test, it was noted that the ThinPrep does cost 
significantly more than the conventional Pap test and given the current lack of scientific 
evidence as to whether the ThinPrep will result in reductions in cervical cancer mortality, it is 
still unclear whether the additional cost is warranted. Nonetheless, it is clear that practitioners 
are increasingly using the ThinPrep instead of the conventional Pap test.  
 
 2. HPV and Cervical Cancer  
 
 The Task Force also briefly reviewed the relationship between Human Papillomavirus 
(HPV) and cervical cancer and issues related to HPV testing.  Research has shown the presence 
of HPV in over 93% of cervical cancers.8  Only certain types of HPV have been linked to the 
development of cervical cancer, including HPV 16 which is estimated to account for 50% of 
cervical cancer, and HPV 18, 31 and 45, which together are estimated to account for 30% of 
cervical cancer.9  While HPV is known to lead to cervical cancer, it is important to note that 
most HPV infections are “transient” and will resolve on their own without medical intervention 
                                                 
7 Presentation of Dr. Michael Jones to the Task Force on December 20, 2005. 
8 National Cancer Institute. Cervical Cancer: Backgrounder. 
http://rex.nci.nih.gov/massmedia/backgrounders/cervical.html 
9 Shah, Keerti V. (1997). “Human Papillomaviruses and Anogential Cancers.” The New England Journal of 
Medicine, 337(19), 1386-1388.  
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and will not develop into cervical cancer.10  Because most cases of HPV will not lead to cervical 
cancer, positive HPV test results provide less information (have less predictive value) than 
negative HPV test results.  
  
HPV testing is increasingly being used to further evaluate Atypical Squamous Cells of 
Undetermined Significance (ASCUS) results from a routine Pap test and determine whether to 
proceed to a colposcopy, a visual examination of the outer portion of the cervix using a 
colposcope to magnify and illuminate the area.  Other drivers behind the use of the HPV test 
include its relatively high sensitivity for detection of high-grade intraepithelial lesion (HSIL) and 
the opportunity it presents to extend the screening interval for women 30 years or older who 
have a negative HPV test result (see Table 2).   
 
 3. HPV Vaccines 
  
 The Task Force reviewed information regarding the status of HPV vaccine development 
and related issues.  It is anticipated that the introduction of HPV vaccines may significantly 
advance cervical cancer prevention.  At the same time, it is important to recognize that there will 
be a significant lag period between the introduction of the vaccines and a reduction in cervical 
cancer mortality rates, due to the latency associated with this disease.  
  
 Two HPV vaccines are currently in the pipeline for licensure by the U.S. Food and Drug 
Administration (FDA): 
 
? Gardasil, being developed by Merck, targets HPV types 6, 11, 16 and 18.  Merck 
submitted its Biologics License Application (BLA) to the FDA in December 2005; and 
 
? Cervarix, being developed by GlaxoSmithKline(GSK), targets HPV types 16 and 18. 
Phase III clinical trials are currently in progress and GSK intends to submit its BLA in 
2006.  
 
Both Gardasil and Cervarix have been shown to be highly effective in preventing persistent HPV 
infection and 100% effective in preventing HPV type-specific associated lesions.11   Task Force 
members noted that while the efficacy of these vaccines is clear, acceptance of the vaccines 
among health care providers, parents and patients is an important practical challenge that will 
need to be addressed to fully realize the potential of these vaccines.  
 
4. “At Your Cervix” Program 
 
 The Task Force invited Tri-County Health Services (TCHS) to present information 
regarding its new cervical cancer prevention program, At Your Cervix.  TCHS, a program of the 
Western Maine Community Action agency, provides reproductive health services and education 
to residents of Androscoggin, Franklin and Oxford counties.  With a two-year grant from the 
                                                 
10 Presentation of Dr. Michael Jones to the Task Force on December 20, 2005. 
11 Diane M. Harper, MD, MPH, MS. Presentation to “The Status Cervical Cancer Vaccine Research” conference, 
Women’s Policy, Inc., Washington, DC, December 6, 2005. 
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Maine Health Access Foundation, TCHS launched At Your Cervix in July 2005 to enhance and 
expand its cervical cancer prevention effort.  As part of At Your Cervix, TCHS has been able to: 
 
? Switch from conventional Pap tests to liquid based Pap tests at no extra charge to clients, 
? Provide HPV testing for all atypical Pap test results,  
? Provide significant discounts for colposcopy, cryosurgery and cervical biopsy 
procedures,  
? Purchase equipment to perform colposcopies in all three counties,  
? Train a clinician in the Loop Electrical Excision Procedure (LEEP), a procedure to 
remove tissue from the cervix, and 
? Initiate new community outreach services including providing information to local 
providers (gynecologists and family practice physicians), distributing At Your Cervix 
information along with heating assistance program applications and hiring a Somali 
outreach worker for the Lewiston-Auburn area.  
 
5. MaineCare Coverage of Cervical Cancer  
 
 a. Cervical Cancer Services and Expenditures 
 
 The Task Force invited representatives of DHHS to present information regarding 
MaineCare services and expenditures related to cervical cancer.  As summarized in Table 3, 
DHHS provided data organized by diagnosis code (the client’s diagnosis) and other data 
organized by procedure code (the clinical procedure performed).  
 
Table 3 
MaineCare Expenditures Related to Cervical Cancer 
State Fiscal Year 200412 
 
 
# Distinct 
Claims 
# Distinct 
Members Total Paid 
By Diagnosis Code (ICD-9)13 
 Routine Pap/Gynecological exam 31,850 23,546 $1,510,609
 Treatment/Evaluation of Abnormal Pap 37,801 21,304 $2,101,414
 Human Papillomavirus (HPV) 1,517 1,256 $131,101
 Cervical cancer treatment or care 1,755 564 $832,836
By Procedure Code 
 Cytopathology for Pap smear 39,290 33,320 $579,418
 Colposcopy/Biopsy/LEEP 2,113 1,825 $118,675
 HPV testing 2,069 1,964 $27,642
 
b. MaineCare Coverage under the Treatment Act  
 
                                                 
12 Source: Maine Department of Human Services, MMDSS 
13 ICD-9 stands for the International Classification of Diseases, 9th Revision, Clinical Modification, which is a 
listing of diagnoses and identifying codes used by physicians for reporting patient diagnoses to health plans. 
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In accordance with the federal Breast and Cervical Cancer Prevention and Treatment Act 
of 2000 (the Treatment Act), Maine enacted Public Law 2001, chapter 439, Part TT to require 
the state’s Department of Health and Human Services to amend its rules to provide full 
MaineCare coverage to women diagnosed with breast or cervical cancer under the Maine Breast 
and Cervical Health Program. Approximately two years following this rule change, Maine 
applied for and received federal approval to also provide MaineCare coverage to those women 
who are not enrolled in MBCHP but who: (a) meet MBCHP eligibility requirements and (b) are 
diagnosed with breast or cervical cancer at a Federally Qualified Health Center participating in 
the MBCHP,14 a less restrictive option allowed under the federal Treatment Act.   
 
To be eligible for MaineCare under the above Treatment Act provisions, a woman must 
be under age 65, not covered by credible health insurance, and have income less than 250% of 
the federal poverty level.15  MaineCare coverage under these rules is continuous for one year as 
long as the woman is receiving cancer treatment.  Since 2001, 88 women with cervical cancer or 
a pre-cancerous cervical cancer condition have been enrolled in MaineCare under these rules.  
Of these women, 64% entered MaineCare with a diagnosis of cervical cancer and 36% entered 
with a pre-cancerous condition.   
 
 
III. Agenda for Future Work 
 
In accordance with the authorizing legislation, the Task Force will not meet from 
December 21, 2005 to April 25, 2006.  To complete its work, the Task Force anticipates holding 
2 meetings between April 26, 2005 and June 30, 2006 (the end of the state fiscal year 2005-
2006) and 4 meetings between July 1, 2006 and November 1, 2006.   
 
Task Force members have identified the following three areas to address at the next meeting: 
 
• Continue to monitor the development of cervical cancer vaccines and invite 
representatives from the U.S. Centers for Disease Control and pharmaceutical companies 
(Merck, GlaxoSmithKline) to brief the Task Force on the vaccines; 
 
• Examine available data on the geographic distribution of women in Maine who are not 
receiving sufficient cervical cancer screening services (including follow-up services after 
an abnormal Pap) and discuss potential strategies to reach these women; and 
 
• Examine available data from the Maine Health Data Organization on cervical cancer 
screening and treatment service utilization and expenditures in both public and private 
health care systems in Maine. 
 
                                                 
14 This change was motivated by LD 143, Resolve, to Improve Access to Breast and Cervical Cancer Treatment, 
which was proposed in the 121st legislature. Ultimately, the LD 143 was not enacted after the department agreed to 
make the changes without legislation. 
15 Specifically the individual must have no “credible coverage” as defined in Section 2701(a) of the federal Public 
Health Service Act.  
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More broadly, the Task Force will utilize its future meetings to: 
 
• Further examine key clinical and technological issues related to cervical cancer 
prevention and detection;   
 
• Identify and address gaps in cervical cancer prevention, detection and education; and 
 
• Develop a statewide cervical cancer prevention plan and strategies for plan 
implementation and coordination.   
 
The Task Force will then submit its findings, recommendations and any proposed legislation in 
its final report, due November 1, 2006, to the joint standing committee of the legislature having 
jurisdiction over health and human services matters.  
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B. One represenlllli\c of a women's hcallh organiza1ion; 
C. One communi cat tons consultant; 
D. One representative o f the American Academy ofPcdmtncs; 
E. One representative of the American Academy of Family Physicians; 
1'. One licensed registered nurse: and 
G. One representative of the :\Iaine Medical Association or i1s successor; 
2. Seven members appoimed by the Speaker of the House of Representatives as follows: 
A. Two members of the I louse ofReprescntatives; 
B. One representative of the American Cancer Society who t$ :.u1 oncologis t; 
C. One representative of the health insmnnce industry; 
D. One representative of the Amen can College of Obstetric tans and Gynccologis1s; 
E. One member of the :\I a me Osteopath• c Association or its successor; and 
F. One person who has sun tvcd cen ical cancer; 
3. rhc mctlica l director of the ~1mnc Cancer Reg1stry or the mcdtca l dtrcctor's designcc; and 
4. The Oio ector of the Mamc Brcasl and Ccr. ocal l lcalth Progmm withtn I he Departmcr1i of 
llealth and Human SerYice~. Bureau of l lealth and other members oft he Burcau of !leah h. as 
necessary to Lhc work of the task force. who serve as ex offic io nonvoting members o f the task 
force. 
When making appointments to the task force, each appointing atttho rity shall ensure thul 
appointees re nee! the composition of the State's population with regard to elhnicity, race and 
age; and be it further 
Sec. 3. Chair. Resolved : That the Senate member shall .<crve as chair and the iillit-namcd 
I louse mcmher shall serve as vice-chair. <lnd be at further 
Sec. 4. Appointments; cnn,·c11in g of task fo •·cc. Resol,·cd: f hat ;til ;tppointtll~.>nts must be 
made; no later than 30 days allcr the cffcctt vc el ate ofthts resolve The nppointuag au thoriucs 
sit<~ II not i f'y 1 he l!x<.!cu tivc Dirccl()r of the Lcgisltt t ivc Council once all arpointmctlt~ have been 
completed. The ch:tir shell call and convene the first meeting of tile t:tsk force by August I , 
2005; and he it fun her 
Sec. 5. Quorum. Resolved: I hat a lll<IJOn ty of the task force cc1nstitu tcs a quorum lot the 
t nu t~action o f' it s business; <uld he it further 
Src. 6. Cnrnmittccs. Resolved: I hat the task force chair m;ty establish conunillccs lo r thl: 
purp<>sc of making speci~ l stuthcs pursuant tu Its duties and may appoin t persons who arc ntlt 
mcmhcrs of the task Ioree to serve on each commtllec as resource persons. Resource persons urc 
voting members or the committees to whtch they arc appOinted. Commtuce~ may meet with the 
Crcquc;ncy needed to accompl ish tlw purpos1.·s of ~his resolve; anu be it funhcr 
Sec. 7. Duties. Resolved: That the task force sh~ ll : 
I . Review statistica l and quali tative data on the prc,·a lcnce <md incadcncc of cervical cancer in 
Maine; 
2.. Review preveDt ive strategies and new technologies. including newly introduced vaccines 
and their effectiveness in preventing and contro l! ing the ri sk of cervical cancer, as well as their 
relative costs; 
J . Identify and examine the strengths and limitations of existing laws, regulations, programs 
and serv ices regarding coverage and awareness of cervical cancer; 
4. Consider reports and testimony fTOm indi,·iduals, local health departments, comnuUJity-
based organizations, voluntary health organizations and other public and private organizations 
statewide lo learn more about their contributions to cervical cancer diagnosis. prevention and 
treatment and their ideas for improving prevention. diagnosis and treatment in Maine; 
5. Develop, in consuliation wi th I he Depanmem ofHealth and Human Servaces. a statewide 
comprehensive cervical cancer prevention plan and stTategies tbr plan implementation and for 
promoting the plan and awareness of the causes . .risk factors, prevention, early detection and 
treatment of cervical cancer to the general pub he. state and local elected officials and various 
public und private organizations. associations, businesses, industries <Lnd agcncie.s; and 
6. Recommend str.uegies for coordination and communication am<mg s tate and local agencies 
and organizations regard ing their involvement in achieving the ~ims of the cervica l cancer 
preventton plan; and be it further 
Sec. 8. Stan assistance. Resolved : ·n,at the Lcgisl~ t ive Council shal l provide necessary 
StJffing services to the task force; and be ll further 
Sec. 9. Compcnsnlion. Resolved : That legisla tive members of the task force arc enti tl ed to 
receive the legislat ive per diem. as de lined m the Maine Revised Statutes. Tille 3, section 2. and 
reimbursement for tnovcl and other ncccss<try expenses f~1r their aucndancc ;tt authori«:ed 
meetings of the t :1~k fo rce. Publ•c mcmbc.:rs not otherwt<e cornpens:ned by thctr entp loycrs or 
~lti tL'r cnti t i v~ that thcy rcpr.:scnt arc cottit lcd to receive reimbursement of necessary expenses and. 
upon'' demonstration of linaJlcial hardship. u per diem equal to the legislative per diem tbr their 
allcoulance Ill :1uthori1cd meetings of the task Ioree; and be 1t further 
Sec. 10. Report. Resolved: 'I h<1t, no Inter than December 7. 2005, the task force shall suhmit 
a11 initia l report to the .Joint Standmg CommJitc.: on llcallh and Human Services und tho.: 
(_jovernor. rhc task force IS not authon;,cd to meet from Dcccmbct 2 1. 2005 to Apnl 25. 2006 or 
to int roduce legis lation. The task force shal l submit its final report to the joint s tanding 
conunittt:c of tl oe Lt:gislaturc havmg.rurisdttuon over health ;md human services matters by 
November I, 2006. The joint standing commtllcC ofth.: Legislature ll<~Vingjunsdiclion over 
health and human services rnauers in the First Regular Session of the 123rd LegislaLUrc rnay 
repon out leg•s lahon on cervica l c;mcer prevention, dctecuon :md cducalion: and be it furtltcr 
Sec. II. Ta~k rurcc runding. Resolved : That the task force shall seck outside funds to Cully 
fund al l costs of the task force. If sufficient outside li.utd ing has not been received hy Scptembt:r 
15, 2005 to fltlly fund al l costs of the task force, no meetings arc authoti zed and no expenses of 
any kind may be incurred or reimbursed. Contributions to suppon the work of the task Ioree may 
not be accepted ii·om any party having pecuniary or other vested interest in the omcome of the 
matters being studied. Any person, other than a state agency, desiring to make a IinaLlCia.l or in-
kind contribution must ccnify to the Legislative Council that il has no pecuniary or other vested 
interest in the outcome of the smdy. Such certification must be made tn the manner prescribed by 
lltc Legislative Council. All contributions are subject to approval by the Legislative Council. All 
funds accepted must be forwarded to the Executi,·e Director of the Legislative Council along 
with an accounti ng record that includes the amount of funds, the date the funds were received, 
ti·om whom the funds were received and the purpose of and any limit~tion on U1c usc of those 
funds. The Executive Director of tlte Legislati ,·e Council shall administer any funds received by 
the task force. ·ntc executive director shall notify the chair of the task force when suffic ienl 
fttnding has been received; and be it funher 
Sec. 12. Appropr·iations and a lloca tions. Resolved: That the following appropriations and 
allocations are made. 
LEGISLATURE 
Mi~cellaneoos Studies 0444 
lnitiauvc: Provides an allocation of Other Special Revenue Funds in the C\'Cnt outside funding is collected to support 
Ute acuvitJCS of lhc Task Force to Srudy CerVICal Cancer Prcvcnt10n. Detection and Education. Jf sufficient outside 
fwJding ~as not been rce''"·cd by September 15, 2005 to fully fund all costs of the tnsk force. no meetings are 
authonzcd nud no expenses of any kind may be IJ)eurrcd or rcomburscd. 
OHrE R Sl' F.CI AI. REVEl\ l ff: 
FUNDS 2005-Q(, 2006-07 
Persona I Scl\'ltcs $880 5880 
All Olloc• $3.600 $3.600 
()TilER ~I'Er'I AI.)U,V I :-JUE 
1'1 fNr>S "I 0"1 A I $4,4811 $4 ,480 
l~mugcnc~· clausr. In ,-icw or the emergency citcclmthc prcmnblc.this resolve takes effect 
wiK·n approved. 
Eni..-cti vc J unc 21, 2005 
APPE DlX B 
Task Force Membership List 
Task Force to Study Cervical C:ancer Prevention, Detection and 
Education 
Appointment(s) by the President 
Sen. Nancy B. Sullivan - Chair 
20 Westwood Omre 
Biddeford. ME 04005 
207 202-5594 
Kolawolo Adownlo Bankolo M.D .. M.S. 
Am<:md;> Lane. l ol #10 
PO Box 5642 
Ellsworth, ME 04605 
Dinn Colo BSN, RN, CPAN 
9 Lemon Stroot 
Ve<lll<l. ME 04401 
Jonnthnn T. Fnnburg M.D., M.P.H. 
PO Oox 1420 
Ell$worth, ME 04005 
MichOol A. Jonos M.D. 
152 Morton Road 
Yarmouth. ME 04096 
Evelyn G. Klellyka MSN, MS, FNP 
Family Planning Assoc. of ME 
P 0 Box587 
Augusla. ME 04332-0567 
James A. Rnczok M.D., FACFP 
489 State Sl, - Webber 1 
Bangor, ME 04401 
207 945-6573 
Appolnlment(s) by the Speaker 
Rep . Usa T. Marrache - Chair 
109 S~ver Street 
Waterville, ME 04901 
207 861-0154 
Rep. James J . Campbell Sr. 
P.O. Box 29 
West Newfield , ME 04095 
Carrie Bolander, D.O. 
24 M1les Center Way 
Damariscotta. ME 04543 
Bob Downs 
RR 1.Box 1580 
Pittsfield, ME 04967 
Susan Miestoldt, M.D. 
Maine Center for Cancer Medicine 
100 u S. Roulo 1 
Scarborough. ME 0407 4 
207 885-7600 
Resolve 2005, Ch. 121 
Senate Member 
Ropresentong Communoca~ons Consull<!nls 
Represenhng Locensod Regostorcd Nursc•s 
Rcproscntong the Amcrocan Ac;oclumy of Podlatnc~ 
Ropoesenhn(lthe Maino Medocal Associallon 
Rcpresen11n9 a Women's Health Orga1111<1tion 
Representong the Academy ol Famly Physioans 
House Members 
House Members 
Representong the Maone Osteopathic Association 
Representong the Health Insurance Industry 
Representing the American Cancer Socoety (Oncologist) 
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Janet Miles 
PO Box 3205 
Auburn, ME 04212-3205 
James Wilberg, M.D. 
35 Stapleford Drive 
Falmouth, ME 04105 
Medical Director, Maine Cancer Registry 
Dr. Molly Schwenn, Medical Director 
Maine Cancer Registry 
State ~louse Station 11 4111 Floor. Key Plaz;~ 
Augusta, ME 04333 
207 207-6945 
Other 
Sharon Jerome Program Director 
MI3CHP. Key Plaza, 4th Floor 
11 Stale House Station 
Augusto , ME 04333 
207 287 ·6895 
Representing Cervu:al Cancer Survivors 
Representing the American College of Obstetricians & 
Gynecologists 
Director. Mame Cancer Regfslly 
Director. Mame Breast & Cerv•cal Health Program, DHHS 
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APPENDIX C 
Agenda for November 16, 2005 Meeting 
I :(t()pm 
I :JOprn 
2:00pm 
3:0(1prn 
4:00pm 
Task Force to Study Cervical Cancer Prevention, 
Detection and Education 
~ovember 16,2005, 1:00pm to 4:00pm 
Room 427, State House 
AGENDA 
Welcome and lntroducuons 
Overview of 1"11~k Force Lc•gislat ion. Duties and Requirements 
Whun; arc we now'1 Ovcrvtcw of Cervical Canr.:cr lnctdcncc and Prevention, 
Lktcction and l:llucauon l11111ntl\ cs 111 M:unc 
• Dr. :-v1olly Sch\\ cnH, Dm!ctor, Mamc Cancer Registry 
• Sharon Gerome. Dtrcctor, Maine Breast and Ccrvtcall lcalth l'rogr~m 
l ~1sk Force Planning 
o Establishing Priorities and Goals 
o Developing Work Plan Schedule 
o Planning for Initial Report due December 2005 
Adjournment 
Next Meeting: Oecember J 6. 2005 :at 1:OOpm in State House Room 427 
Staff: 
1\tcole Dube. Office of Policy and Legal Analysts. 287-1670. ematl: !1!£9le.dube(ailegtslantre.maine.uov 
Lucw Nixon. Office of Policy and Legal Analysis, 287-1670. cmatl : lucia.nixon@le!ili.Jill!'.Le.maine.gov 
APPENDI X 0 
Agenda fo r December 20, 2005 :\'1ecting 
I ::lOpm 
1:45pm 
2:00pm 
2:30pm 
3:00pm 
3:30pm 
J:4;:ipm 
4:30pm 
.Staff: 
Task Force to Study Cervical Cancer Prevention, 
Detection and Education 
December 20, 2005, I ::IOpm to 4:30pm 
Room ~27, S tate House 
AGE DA 
I nt roduct1 ons 
'1\:chno logy I.-sues !Jr Junes 
• II PV /vacc111c de\'clopmcnt 
• Thin prep vs. convcntionnl p;tp 
• Women who arc screened but for whom screening fai Is 
Wc~tem Maine Cnmmumt) Action Program, "At Your Cervix ' ' 
Saru I lares. 7 n · Count1 /lealrh St•J-vtces 
MaineCan: con:rasc of cer. ical cancer screeningilrealmcnl 
Linda Schumadwr ami Mauro Howtlrd, fJN!IS 
Repor1 !Jack on the Cervtcal Cancer Summit, Rep. Marraclte 
lnil ial Report (Due December ~3)- Review draft 
Adjoumment 
Nicole Dube, Office or Policy and Legal Analysis, 287-1670, cmml: mcole.dube((i;lemslg_tur".m'!)n~.gQ.y 
Lucia Nixon, Office of Polley and Leg.al Analysis, 287-1670. email: lucin.ni.,on@.kgi;;lattrre.mnine.gov 
